Powerful Clinical Performance in International Patient Population

Excellent Clinical Performance through 2 Years

*TLF = cardiac death + target vessel MI + target lesion revascularization. The FANTOM II primary endpoint was Major Adverse Cardiac Events (MACE) = cardiac death + all MI + target lesion revascularization. The 24-month MACE rate was 5.0%.


  • 240 patients with clinical follow-up
  • 153 matched OCT image pairs
  • 28 centers
  • 8 countries

12-month Clinical Results presented at EuroPCR 2017

: FANTOM II 2-Year Datasheet

Excellent Vessel Healing & Scaffold Coverage

FANTOM II OCT analysis: matched OCT images at baseline, 6 months, and 24 months, n=256

Change in mean scaffold area

Change in mean scaffold area

Change in mean luminal area

Change in mean luminal area

Strut coverage

Strut coverage

FANTOM II case sample: matched OCT images at baseline, 6 months, and 24 months1


Follow-up 6 Mo.

Follow-up 24 Mo.

FANTOM Global Clinical Program

REVA Medical is committed to advancing the field of BRS. The FANTOM Clinical Program is designed to evaluate performance in a variety of patient and lesion types.

FANTOM Global Clinical program


  1. Abizaid, A. New 24-month data from the FANTOM II clinical trial. Presented EuroPCR 2018.
  2. Ellis S, Kereiakes, D. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent: ABSORB III. Presented ACC 2017.
  3. Haude M, et al. Short and midterm safety, clinical performance and multimodality imaging results of the drug-eluting absorbable metal scaffold: Combined data of the BIOSOLVE-II and BIOSOLVE-III trials. EuroPCR 2017.
  4. Stone G, et al. Randomized Comparison of Everolimus- and Paclitaxel-Eluting Stents 2-Year Follow-Up From the SPIRIT IV Trial. JACC 2011;58(1):19-25.
  5. Mauri L. 2-year clinical outcomes from the pivotal RESOLUTE US study. Presented ACC 2012.
  6. Holm, N. REVA Fantom II performance and healing patterns by OCT. REVA Symposium EuroPCR 2017.